Head of the Class: An Interview with MIT's Robert Langer
Perhaps no single person represents the biomedical industry's past three decades of evolution better than MIT professor Bob Langer. He's counted as the founder of more than two dozen companies, reflecting a commitment to both making new discoveries and getting them into the hands of people who can benefit from them.
You may also be interested in...
Siemens Healthineers' acquisition of radiation oncology company Varian Medical Systems creates an oncology giant. Analysts disagree on whether its the right move for the companies.
Pfizer is up against AstraZeneca and Sanofi in developing competing approaches to tackling the unmet need in respiratory syncytial virus (RSV). But earlier failures mean all players will need much more data to sway regulators.
In a busy second quarter for Teva, a COVID-19 slump acted as a correction to the related boost in demand seen in the first quarter of 2020.